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History of the World Allergy Organization: In 1951, the
leaders in allergy from all over the world came
together to form the International Association of Aller-
gology and Clinical Immunology (IAACI). For the next
60 years, the allergy world converged at the IAACI
triennial meetings, which became biennial in 2003.
The international meetings, originally named the Inter-
national Congress of Allergology and Clinical Immu-
nology (ICACI), are now the World Allergy Congress
(WAC) hosted by the World Allergy Organization
(WAO). Everyone who has aspired to have worldwide
recognition has played a part in IAACI-WAO. The His-
tory of the World Allergy Organization traces the
global arc of the allergy ﬁeld over the past 60 years.
The current ofﬁcers of WAO elected to focus on this
rich history, inviting prominent leaders who are inter-
ested in being part of this history project to write about
their time with IAACI-WAO. This series will be pre-
sented in Cancún, México, as part of the XXII World
Allergy Congress (December 4-8, 2011). Leading up to
the Congress in Cancún, the World Allergy Organiza-
tion Journal is presenting segments of the History as
part of the “Notes of Allergy Watchers Series.” Please
enjoy.
dMichael A. Kaliner, MD
Historian and Past President (2006–2007)
World Allergy Organization
My own golden anniversary of 50 years in allergy coin-cides with the World Allergy Organization’s (WAO’s)
anniversary of 60 years of service to the specialty, and my
good fortune of being in the right place at the right time
eventually led to the honor of being elected President of the
organization!
A NEW IMMUNOGLOBULIN ISOTYPE
In 1961, after 3 years at medical school, I had a holiday
job at the Department of Clinical Chemistry at the University
Hospital in Uppsala working as a laboratory technician.
Uppsala has a very good tradition in the ﬁeld of separation
and characterization of serum components, and I was asked to
establish immunoelectrophoresis for characterization of immu-
noglobulins and to study sera from patients with suspected
immunological diseases. A research group was then formed
with the aim to isolate and characterize human immuno-
globulins. My colleague Hans Bennich was interested in the
isolation and characterization of human immunoglobulins,
which included fragmentation with reduction/alkylation and
digestion by proteolytic enzymes. I raised antisera in rabbits to
identify the various fragments but also to set up immunoassays
to characterize and quantitate the 3 known immunoglobulin
classes and their constituents, to support clinical investigations
of patients with suspected disturbances in this area, for
example, immune deﬁciencies and multiple myeloma.
In June of 1965, I found a myeloma protein where I
could not identify the isotype. It was an immunoglobulin
with lambda light chains, unique antigens on the Fc fragment,
and a molecular weight in the order of 200,000 daltons,
indicating that it represented a new immunoglobulin isotype,
which we provisionally called IgX. A hemagglutination tech-
nique for diagnosis of pregnancy was developed for IgX, and
in January 1967, IgX was detected in serum of healthy
individuals, thus fulﬁlling all the criteria for a new immuno-
globulin isotype. We provisionally designated this isotype by
the initials of the individual from which it was derived, IgND.
As a result, the ﬁnding of increased levels of IgND in allergic
asthma and the development with Leif Wide of the test for
IgND antibodies to common allergens, RAST, were ﬁnalized
and published. Interestingly, these 2 approaches to describe
serological events in allergy are still the basis of in vitro
diagnosis of IgE-mediated allergy.
During 1966, much effort was invested in understand-
ing IgX. A collaboration was started with Dennis Stanworth
from Birmingham, United Kingdom, who had spent a lot of
time characterizing reaginic activity to horse dander allergen
by the Prausnitz–Küstner test. We aimed to test if IgX could
block the P–K reaction, which was indeed the case, and later
to characterize the structure responsible for this activity,
which was found to be the Fc fragment.
From the fall of 1966, we had close contacts with
D. S. Rowe, then at the World Health Organization Interna-
tional Reference Centre for Immunoglobulins in Lausanne. We
sent him puriﬁed IgND immunoglobulin, fragments of IgND,
and antisera speciﬁc for the 2 antigenic epitopes we had found
on the Fc fragment, and he was able to conﬁrm our ﬁndings.
In 1966–1967, Kimishige Ishizaka and Teruko Ishizaka,
then in Denver, had published their ﬁndings on gE, reporting
that their anti-gE could block the P–K reaction with ragweed
allergen and that when injected in the skin, it gave an erythema,
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hence the “E.” Early in 1967, we sent a mail informing them of
our ﬁnding of IgND and invited them to a comparison with
their gE. When it was found, and conﬁrmed, that their anti-gE
reacted with isolated IgND and that anti-IgND inhibited the
reaginic activity of their gE-containing fractions, contacts with
the World Health Organization were intensiﬁed. In February
1968, a workshop was held at the Reference Centre in
Lausanne with Kimishige Ishizaka representing the gE leg
and Hans Bennich and I the IgND leg of what was then, for
the ﬁrst time, ofﬁcially accepted as a new class of human
immunogloblins, designated IgE.1
NEW EXPERIENCES IN NATIONAL AND
REGIONAL ALLERGY SOCIETIES
Because our initial ﬁndings on IgND were published in
the Lancet, the message spread quickly (Fig. 1). In 1968, I
participated in my ﬁrst congress of the European Academy of
Allergology and Clinical Immunology (EAACI) in Florence,
Italy. In 1969, we presented our data at the Royal Society of
Medicine in London invited by J. L. Turk, and the same year
we visited for the ﬁrst, of many times, Kimishige Ishizaka and
Teruko Ishizaka in Denver. In 1972, Sheldon C. Siegel
invited me to my ﬁrst annual meeting of the American Acad-
emy of Allergy and Immunology, nowadays the American
Academy of Allergy Asthma and Immunology (AAAAI),
held in San Francisco in 1972, to present our ﬁndings. At
the meeting, the Academy kindly nominated me as Interna-
tional Fellow, the ﬁrst appreciation I had the pleasure of
receiving from an allergy society!
During the 1970s, I spent time with I. Leonard
Bernstein at the University of Cincinnati as visiting professor,
and I was invited several times to the United States, where I
enjoyed visiting many of the very best scientists and research
centers in the ﬁeld of allergy and immunologydK. Frank
Austen and Albert L. Sheffer in Boston; Philip S. Norman
and Lawrence Lichtenstein in Baltimore; John A. Anderson in
Detroit; Roy Patterson in Chicago and Gerald J. Gleich at the
Mayo Clinic. Interestingly, all except one of those notable
individuals became President of AAAAI.
In the late 1970s, I was approached by Bengt Samuelsson,
then Rector of the Karolinska Institute, and invited to apply
for a position as Professor of Clinical Immunology, at the
Karolinska Institute, combined with being Head of the
Department of Clinical Immunology, at the Karolinska Hosp-
ital. I accepted, of course, and started my work in the summer
of 1980. Since this was a new discipline at Karolinska I had
to build up the organization from scratch. It is not so easy
to handle people, equipment, money, and politicians when
your experience is based on immunizing rabbits and perfor-
ming immunochemical laboratory bench work. In addition to
building up a Department of Clinical Immunology, I was also
involved in administration within the Karolinska Hospital.
During 1984–1989, and as one of the Chief Physicians, I
was responsible for the hospital’s obligations to all clinical
research. That was an interesting time that gave me a lot of
experience, as were the 6 years in the scientiﬁc committee of
the H.R.H. Queen Silvia of Sweden Foundation for Research on
Children’s Handicap.
I had the pleasure of working as President of the
Swedish Association of Allergology (SFFA), and when I was
elected a member of the Executive Committee of the
European Academy of Allergy and Immunology (EAACI)
and in 1992 became President of EAACI, this experience was
very useful. We updated the infrastructure of EAACI,
engaged a professional executive ofﬁce, introduced individual
memberships, made a deal with the publishers of Allergy to
make it the ofﬁcial journal of EAACI, and negotiated a long-
term sponsor agreement with a group of companies, the
so-called Founder Sponsors. When my 10 years as Editor-
in-Chief of Allergy expired in 2002, it was a pleasure to hand
over the responsibility to Jean Bousquet of Montpellier.
A NEW GLOBAL STRATEGY FOR AN
INTERNATIONAL ALLERGY ORGANIZATION
As my term of ofﬁce in EAACI ended in 1997, I had the
pleasure of being nominated President of the International
Association of Allergology and Clinical Immunology (IAACI).
Again, it was time for an update. We held a strategic planning
session in Saltsjöbaden near Stockholm, where I worked for
the ﬁrst time with Karen Henley Davies, the newly appointed
Global Projects Director for WAO, who from then on provided
essential Europe-based support for my presidency. During a
premeeting discussion with Rick Iber, IAACI Executive
Director, in the kitchen of the hotel, our ﬁrst major idea was
to recommend a change of the name of the organization to
make it stand out among the many similar organizations
relating to allergy and clinical immunology. We needed a name
to reﬂect the new overarching role that the organization needed
to take on if it was to survive in the global environment and to
FIGURE 1. Gunnar Johansson and Hans Bennich in
a laboratory demonstrating the washing of particles in
a centrifuge, circa. 1967. Reprinted from Johansson2 with
permission from Elsevier.
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take responsibility for communication within the world of
allergy. Karen and I came up with the name World Allergy
Organization (WAO), which was proposed to the Executive
Committee, meeting with great enthusiasm from some and
with great caution by others! There was some questioning to
start with whether it was too close to World Health Organiza-
tion, I didn’t think so. And it ﬁt very well with our ideas to save
the IAACI and move in a different direction by determining
what really was needed in our specialty at a global level. There
are so many allergy societies, and we needed to take on a clear
and necessary role to justify our existence. Much discussion
ensued on whether the name should be World Allergology
Organization but doubters were persuaded that World Allergy
Organization would enable us to cover many more issues
relating to allergic disease that those relating purely to the
clinical practice of the specialty. It was also agreed, although
with reservations, that Clinical Immunology could be omitted
from the new name.
At that time, IAACI was rather small, built on personal
contacts and friends, not really taking responsibility for
anything like education, communication, or political issues.
The idea with WAO was to be the opposite, to really have
representation from all over the world, and to make sure that
the various national societies did join so that we had the
possibility of communicating with them. I still think that this
is very very important for allergy as a specialty because
there remains a big risk that it will be pushed into a corner
by respiratory physicians, laboratory doctors, dermatolo-
gists, pediatricians and so forthdall of whom think that
allergy is a little part of their business, but all of whom really
worry about everything else but allergy. At that time, the
international members were there for geographical balance,
but it didn’t mean that one was working actively on
some kind of communication or collaboration with, for
example, the Japanese Society of Allergology or the
AAAAI. The old Europeans were in charge and did what
they wished to do, and while that might have been great in
the beginning, changes were vital for the future of the orga-
nization. We brought in many new young people who were
really prepared to work hard for the organization instead of
using it as a personal career step.
I was pleased to have the opportunity of introducing
new programs, such as the educational program, Global
Resources in Allergy (GLORIA). This started as collabo-
ration with EAACI to disseminate their new guidelines on
the management of allergic rhinitis and then expanded to
incorporate all aspects of allergic disease. GLORIA is
now a comprehensive series of 14 lectures on major topics
in allergy that can be downloaded from the WAO Web site
(www.worldallergy.org). The program was originally spon-
sored by a group of industry supporters enabling lectures to
be given around the world, and local faculties were trained
to present the lectures to educate the primary care doctors in
their countries.
This mirrored the new kind of sponsorship, the
“Founder Sponsors” group, which I had introduced for the
EAACI. Before this arrangement, the individual in charge
of the congress, the local chair, was able to run the cong-
ress as a private business and to make special deals with
individual companies. I thought that was unfair. If compa-
nies sponsor the congress, then the society behind the con-
gress should have access to any money left over after the
congress and to make it available for educational projects or
grants for young people or whatever other local needs had
been identiﬁed. After the 1995 meeting, I sat down with
Ulf Säther at Pharmacia Diagnostics and convinced them
that this was a good idea, and then we tried to recruit other
companies that were prepared to be involved and to sponsor
3 congresses in a row at a given amount of money. For that
commitment, they would have clearly deﬁned sponsorship
beneﬁts to look forward to like a seminar, advertisements,
and a hospitality room. To start with, this was a very difﬁ-
cult discussion because they hadn’t all heard about it and
they didn’t all like it; they thought they should be allowed
to handle this individually, but after several meetings, the
idea was accepted and liked and became a successful long-
term commitment. Adopting a similar policy for GLORIA
ensured that no one company dominated and no conﬂict of
interest would exist.
We also initiated the WAOWeb site (www.worldallergy.
org). This was originally trademarked as GAINdthe
Global Allergy Information Network, with the aim to cre-
ate links between all the reputable Web sites on allergy and
to provide original information and education where it
was not already available from other sites. This attracted
development funding from Aventis, with the personal sup-
port of Keith Allan, who has continued to support the site
as he has moved within the pharmaceutical industry over
the years!
A NEW CENTURY WITH INCREASED
ALLERGY PREVALENCE
At “my congress,” organized magniﬁcently by Connie
Katelaris, in Sydney in 2000, I became past president
(Fig. 2). I continued to work with numerous WAO projects,
most notably coediting, with Tari Haahtela, the Prevention
of Allergy and Allergic Asthma book that had started as
a collaboration with World Health Organization but then
became a WAO standalone project after a number of
changes in WHO policy relating to their relationships with
not-for-proﬁt organizations.3 I was then invited to form the
WAO Nomenclature Committee to agree a revised nomen-
clature for allergy, endorsed by EAACI and WAO and its
70 member societies. You can’t communicate with people
unless you have one and the same language. If someone is
talking about atopy as clinical symptoms, and someone else
is using atopy as a deﬁnition of the genetic familiar tendency
to become IgE sensitized, of course they have problems
understanding each other. Considerable work ensued in pro-
moting the new nomenclature to encourage its uptake,
including translations and publications in WAO Member
Society journals, and hopefully, we now better understand
each other, and our ﬁeld of expertise can continue to ﬂourish
and develop.4
WAO is doing ﬁne and is living up to our expectations,
thanks to preceding presidents like Terumasa Miyamoto
of Tokyo and Alberto Oehling of Pamplona, and I am
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delighted at the way the organization has continued to
grow under the direction of my presidential successors.
The organization has managed to establish positive relation-
ships with many important national allergy societies, but
there is still a lot to do. There are still aspects of allergy
that need to be further investigated at a scientiﬁc level.
Allergy is very important because it is part of many many
clinical specialties and because it is a special kind of
disorder with special mechanisms requiring special appro-
aches to treatment and diagnosis. The major problem is that
the prevalence of allergic disease is so high and in many
areas of the world is increasing. There are so many millions
of patients who need access to a physician with some
knowledge about allergy so that they can be referred to the
right kind of specialist, and this remains one of our major
challenges.
Much has happened in the past 60 years, but there is
still much to do!
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FIGURE 2. Cover of the ﬁnal program of the XVII
International Congress of Allergology and Clinical Immunology
in Sydney, Australia, in 2000.
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